Cargando…

Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort

OBJECTIVE: This study aimed to construct a nomogram to effectively predict the 3 years and 5 years overall survival of patients with thymic squamous cell carcinoma (TSCC). METHOD: From 2000 to 2019, a total of 355 patients with TSCC were enrolled in our research from the Surveillance, Epidemiology,...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yelan, Xu, Feiqi, Zheng, Shuai, Gu, Xiaodong, Sun, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281918/
https://www.ncbi.nlm.nih.gov/pubmed/37340185
http://dx.doi.org/10.1007/s12672-023-00720-4
_version_ 1785061084575563776
author Guan, Yelan
Xu, Feiqi
Zheng, Shuai
Gu, Xiaodong
Sun, Yan
author_facet Guan, Yelan
Xu, Feiqi
Zheng, Shuai
Gu, Xiaodong
Sun, Yan
author_sort Guan, Yelan
collection PubMed
description OBJECTIVE: This study aimed to construct a nomogram to effectively predict the 3 years and 5 years overall survival of patients with thymic squamous cell carcinoma (TSCC). METHOD: From 2000 to 2019, a total of 355 patients with TSCC were enrolled in our research from the Surveillance, Epidemiology, and End Results (SEER) database and used as the training cohort. 106 patients were included from the Zhejiang Cancer Hospital, for the external validation cohort. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index and curve of calibration. The two cohorts were divided into low-risk and high-risk subgroups based on the median risk score. RESULTS: Age (p = 0.002), stage (p = 0.003), surgery therapy (p < 0.001), and radiotherapy (p = 0.030) were the independent prognostic factors for overall survival and were incorporated in the prognostic model. The discrimination of the nomogram revealed a good prognostic accuracy and clinical applicability as indicated by C-index values of 0.696 (95% confidence interval [CI] 0.676–0.716) and 0.717 (95% CI 0.640–0.794) for the training cohort and external validation cohort, respectively. In addition, the two cohorts were divided into a high-risk group and a low-risk group according to the median risk score. Significant differences in overall survival were observed between the high-risk and low-risk groups in the training (p < 0.0001) and external validation cohort (p < 0.0001). CONCLUSION: We developed a nomogram to predict 3- and 5 year survival rate for TSCC. This nomogram provides a convenient and reliable tool for assessing the condition of patients with TSCC and assisting clinicians in making decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00720-4.
format Online
Article
Text
id pubmed-10281918
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-102819182023-06-22 Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort Guan, Yelan Xu, Feiqi Zheng, Shuai Gu, Xiaodong Sun, Yan Discov Oncol Research OBJECTIVE: This study aimed to construct a nomogram to effectively predict the 3 years and 5 years overall survival of patients with thymic squamous cell carcinoma (TSCC). METHOD: From 2000 to 2019, a total of 355 patients with TSCC were enrolled in our research from the Surveillance, Epidemiology, and End Results (SEER) database and used as the training cohort. 106 patients were included from the Zhejiang Cancer Hospital, for the external validation cohort. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index and curve of calibration. The two cohorts were divided into low-risk and high-risk subgroups based on the median risk score. RESULTS: Age (p = 0.002), stage (p = 0.003), surgery therapy (p < 0.001), and radiotherapy (p = 0.030) were the independent prognostic factors for overall survival and were incorporated in the prognostic model. The discrimination of the nomogram revealed a good prognostic accuracy and clinical applicability as indicated by C-index values of 0.696 (95% confidence interval [CI] 0.676–0.716) and 0.717 (95% CI 0.640–0.794) for the training cohort and external validation cohort, respectively. In addition, the two cohorts were divided into a high-risk group and a low-risk group according to the median risk score. Significant differences in overall survival were observed between the high-risk and low-risk groups in the training (p < 0.0001) and external validation cohort (p < 0.0001). CONCLUSION: We developed a nomogram to predict 3- and 5 year survival rate for TSCC. This nomogram provides a convenient and reliable tool for assessing the condition of patients with TSCC and assisting clinicians in making decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-023-00720-4. Springer US 2023-06-20 /pmc/articles/PMC10281918/ /pubmed/37340185 http://dx.doi.org/10.1007/s12672-023-00720-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Guan, Yelan
Xu, Feiqi
Zheng, Shuai
Gu, Xiaodong
Sun, Yan
Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title_full Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title_fullStr Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title_full_unstemmed Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title_short Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
title_sort survival nomogram for patients with thymic squamous cell carcinoma, based on the seer database and an external validation cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281918/
https://www.ncbi.nlm.nih.gov/pubmed/37340185
http://dx.doi.org/10.1007/s12672-023-00720-4
work_keys_str_mv AT guanyelan survivalnomogramforpatientswiththymicsquamouscellcarcinomabasedontheseerdatabaseandanexternalvalidationcohort
AT xufeiqi survivalnomogramforpatientswiththymicsquamouscellcarcinomabasedontheseerdatabaseandanexternalvalidationcohort
AT zhengshuai survivalnomogramforpatientswiththymicsquamouscellcarcinomabasedontheseerdatabaseandanexternalvalidationcohort
AT guxiaodong survivalnomogramforpatientswiththymicsquamouscellcarcinomabasedontheseerdatabaseandanexternalvalidationcohort
AT sunyan survivalnomogramforpatientswiththymicsquamouscellcarcinomabasedontheseerdatabaseandanexternalvalidationcohort